Please find the enclosed report of the Company as per the captioned subject for your reference.
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
AstraZeneca Pharma India Ltd has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, as required under SEBI Regulation 24A. The report, issued by Practicing Company Secretaries M/s. Makarand M. Joshi & Co., confirms that the company has fully complied with all applicable SEBI regulations including the Listing Regulations, Takeover Regulations, and Insider Trading Regulations. No deviations, violations, or fines were reported during the review period. The report also notes that previous observations from FY 2024-25 regarding Audit Committee quorum have been addressed - the company has since automated its Audit Committee processes to ensure strict adherence to regulatory requirements.
This is a positive filing for shareholders as it confirms AstraZeneca Pharma India maintained full regulatory compliance throughout FY 2025-26. The company has also resolved previous regulatory concerns raised by NSE and BSE regarding Audit Committee quorum, demonstrating commitment to good corporate governance.